| Literature DB >> 34177652 |
Teodor T Postolache1,2,3, Abhishek Wadhawan1,4, Dan Rujescu5, Andrew J Hoisington2,6,7, Aline Dagdag1, Enrique Baca-Garcia8,9,10,11,12,13,14, Christopher A Lowry2,7,15, Olaoluwa O Okusaga1,16,17, Lisa A Brenner2,7,18.
Abstract
Within the general literature on infections and suicidal behavior, studies on Toxoplasma gondii (T. gondii) occupy a central position. This is related to the parasite's neurotropism, high prevalence of chronic infection, as well as specific and non-specific behavioral alterations in rodents that lead to increased risk taking, which are recapitulated in humans by T. gondii's associations with suicidal behavior, as well as trait impulsivity and aggression, mental illness and traffic accidents. This paper is a detailed review of the associations between T. gondii serology and suicidal behavior, a field of study that started 15 years ago with our publication of associations between T. gondii IgG serology and suicidal behavior in persons with mood disorders. This "legacy" article presents, chronologically, our primary studies in individuals with mood disorders and schizophrenia in Germany, recent attempters in Sweden, and in a large cohort of mothers in Denmark. Then, it reviews findings from all three meta-analyses published to date, confirming our reported associations and overall consistent in effect size [ranging between 39 and 57% elevation of odds of suicide attempt in T. gondii immunoglobulin (IgG) positives]. Finally, the article introduces certain links between T. gondii and biomarkers previously associated with suicidal behavior (kynurenines, phenylalanine/tyrosine), intermediate phenotypes of suicidal behavior (impulsivity, aggression) and state-dependent suicide risk factors (hopelessness/dysphoria, sleep impairment). In sum, an abundance of evidence supports a positive link between suicide attempts (but not suicidal ideation) and T. gondii IgG (but not IgM) seropositivity and serointensity. Trait impulsivity and aggression, endophenotypes of suicidal behavior have also been positively associated with T. gondii seropositivity in both the psychiatrically healthy as well as in patients with Intermittent Explosive Disorder. Yet, causality has not been demonstrated. Thus, randomized interventional studies are necessary to advance causal inferences and, if causality is confirmed, to provide hope that an etiological treatment for a distinct subgroup of individuals at an increased risk for suicide could emerge.Entities:
Keywords: Toxoplasma gondii; aggression; impulsivity; self-directed violence; suicidal behavior; suicide; suicide attempts
Year: 2021 PMID: 34177652 PMCID: PMC8226025 DOI: 10.3389/fpsyt.2021.665682
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1Intermediate phenotypes for suicidal behavior. Model displaying candidate genes, endophenotypes, and environmental risk factors implicated in suicidal behavior that may lend themselves to further study in animal model systems. The upper portion shows the cumulative liability for suicide originating in the dynamic interplay between environmental, genetic, and epigenetic factors. Attempted suicide is a major risk factor but does not always predate suicide as suggested in the figure. Gene loci, genes, candidate endophenotypes and links among these factors remain to be discovered. Many psychosocial stressors are not listed in the figure because of the biological focus. Specific gene loci and genes were not included because of the current limitations in knowledge, and the absence of adequate replication at the time of publication. TBI, traumatic brain injury. T. gondii finds its place on the right upper side under “Harmful” environmental factors (Allergens/Pathogens) [Reprinted with permission from (20); Copyright (2020); License link: http://creativecommons.org/licenses/by/4.0/].
Individual studies used in the three meta-analyses with suicide attempts as the outcome measure presented in the article.
| Arling et al. ( | Yes/Yes/Yes | USA | Case-control | EIA (S) | IgG | P: NA | P: (F:47, M:34) C: (F:NA, M:NA) | Yes | Mood disorders and healthy | Mood disorders | 1.26 (0.56–2.83) |
| Yagmur et al. ( | Yes/Yes/Yes | Turkey | Case-control | ELISA | IgG | P: (24.31 ± 7.57) | P: (F:159, M:41) C: (F:155, M:45) | No | Healthy | Psychiatric disorders | 1.79 (1.18–2.71) |
| Okusaga et al. ( | Yes/Yes/Yes | Germany | Cross-sectional | EIA (S) | IgG | P: (38.6 ± 11.1) | P: (F:137, M:214) C: (F:213, M:386) | Yes | Schizophrenia | Schizophrenia | 1.18 (0.90–1.54) |
| Pedersen et al. ( | Yes/Yes/Yes | Denmark | Cohort | EIA | IgG | P: (15, 61) | P: (F:1,005) C: (F:44,783) | Yes | Self-directed violence (mothers giving birth to first child) | Self-directed violence (mothers giving birth to first child) | 1.28 (1.12–1.47) |
| Zhang et al. ( | Yes/Yes/No | Sweden | Cross-sectional | ELISA | IgG | P: (38.4 ± 14.4) | P: (F:31, M:23) C: (F:19, M:11) | Yes | Healthy | Psychiatric disorders | 2.75 (0.97–7.83) |
| Alvarado-Esquivel et al. ( | Yes/Yes/Yes | Mexico | Case-control | EIA | IgG | P: (34.01 ± 10.25) | P: (F:119, M:37) C: (F:76, M:51) | Yes | Psychiatric disorders | Psychiatric disorders | 0.55 (0.20–1.49) |
| Samojłowicz et al. ( | Yes/Yes/Yes | Poland | Case-control | IFA | IgG | P: (20, 89) | P: (F:5, M:36) C: (F:7, M:79) | No | People who died suddenly due to disease | People who died suddenly due to suicide | 1.65 (0.77–3.55) |
| Alvarado-Esquivel et al. ( | No/Yes/No | Mexico | Case-control | EIA | IgG | (36.01 ± 12.48) | (F:123, M:26) | Yes | Psychiatric disorders | Psychiatric disorders | 0.27 (0.06–1.26) Seropositive: 2/57 (3.5%) v. 13/92 (14.1%) |
| Fond et al. ( | Yes/Yes/Yes | France | Cross-sectional | ELISA (S) | IgG | P: (48.1 ± 12.0) | P: (F:29, M:25) C: (F:47, M:51) | Yes | Bipolar disorder type I and II | Bipolar disorder type I and II | 2.00 (0.86–4.63) |
| Fond et al. ( | Yes/Yes/Yes | France | Cross-sectional | ELISA (S) | IgG | P: (36.2 ± 11.4) | P: (F:13, M:30) C: (F:18, M:53) | Yes | Schizophrenia or schizoaffective disorder | Schizophrenia or schizoaffective disorder | 1.42 (0.63–3.18) |
| Coccaro et al. ( | No/Yes/No | USA | Cross-sectional | ELISA (S) | IgG | P: (36.1 ± 8.3) | P: (F:45, M:64) C: (F:52, M:58) | No | Different states (healthy, psychiatric and Intermittent Explosive Disorder) | Different states (healthy, psychiatric and Intermittent Explosive Disorder) | 1.42 (0.59–3.44) |
| Coryell et al. ( | Yes/Yes/Yes | USA | Case-control | ELISA | IgG | P: (17.5 ± 1.7) | P: (F:13, M:4) | No | Adolescents with mood disorders | Adolescents with mood disorders | 5.93 (0.78–45.40) |
| Sugden et al. ( | Yes/Yes/Yes | New Zealand | Cohort | EIA | IgG | P: (38) | (F:414, M:423) | No | Psychiatric disorders | Psychiatric disorders | 2.60 (0.96–7.01) |
| Ansari-Lari et al. ( | Yes/Yes/Yes | Iran | Case-control | ELISA | IgG | P: (43.5 ± 8.1) | P: (F:10, M:32) C: (F:17, M:40) | Yes | Schizophrenia | Schizophrenia | 1.03 (0.42–2.51) |
| Samojłowicz et al. ( | No/Yes/No | Poland | Case-control | ELISA | IgG | P: (18, 89) | P: (F:13, M:113) C: (F:25, M:140) | No | Individuals who died as a result of disease | Individuals who died as a result of the risky behavior | 1.66 (1.04–2.66) |
| Bak et al. ( | Yes/Yes/Yes | South Korea | Case-control | CLIA | IgG | P: (18, 80) | P: (F:69, M:66) C: (F:80, M:75) | Yes | Healthy | Depressive symptoms | 2.49 (1.06–5.82) |
| Fond et al. ( | No/Yes/Yes | France | Cohort | EIA (S) | IgG | (32.0 ± 8.6) | (F:66, M:184) | No | Schizophrenia | Schizophrenia | 1.27 (0.26–6.25) |
| Burgdorf et al. ( | Yes/Yes/No | Denmark | Case-control | ELISA (S) | IgG | P: (37.4) | P: (F:377, M:278) C: (F:NA, M:NA) | No | Blood donors (psychiatric disorders without registered suicide attempt) | Blood donors (psychiatric disorders with registered suicide | 1.25 (1.04–1.49) |
| Sari and Kara ( | No/Yes/No | Turkey | Case-control | ELISA | IgG | P: (12, 17) | P: (F:43, M:7) C: (F:43, M:7) | No | Healthy | Psychiatric disorders | 7.44 (0.37–147.92) |
| Yalin Sapmaz et al. ( | No/Yes/No | Turkey | Cross-sectional | ELISA | IgG | (15.6 ± 1.59) | (F:31, M:6) | No | Depression | Depression | 94.50 (7.45–1198.62) |
C, control; CI, confidence interval; CLIA, chemiluminescent immunoassay; EIA, enzyme immunoassay (S): solid-phase EIA; ELISA, enzyme-linked immunosorbent assay (S): solid-phase ELISA; F, female; IF, indirect immunofluorescence; IgG, immunoglobulin G; IgM, immunoglobulin M; IU, International unit; M, male; mL, milliliter; OR, odds ratio; P, patient; PANSS, Positive and Negative Syndrome Scale; S.D., standard deviation; SDV, self-directed violence; SES, socioeconomic status; v., versus.
Data of cases are presented first, control population second.
Figure 2Forest plot showing an association between T. gondii infection and suicide attempts as reported in a meta-analysis by Sutterland et al. (80) using the random effects model. Serointensity has not been presented, and, thus, the first study on T. gondii infection and suicide attempt appears as negative [Modified and reprinted with permission from (80); Copyright (2019); with permission from Cambridge University Press; License # 4963421068137].
Figure 3Results (odds ratios and 95% confidence intervals) from the individual studies and the meta-analysis by Soleymani et al. (98). The first study from the Postolache group, by Timothy Arling is wrongly identified as Timothy et al. instead of Arling et al. (74). Furthermore, studies that have identified associations between serointensity (but not seropositivity), such as Arling et al. (74) and Okusaga et al. (95) appear as carrying no significant association [Modified and reprinted with permission from (98); Copyright (2020); with permission from Springer Nature; License link: http://creativecommons.org/licenses/by/4.0/].
Figure 4Forest plot showing a correlation between T. gondii infection (IgG) and suicide attempts as reported in a meta-analysis from 21 data sets by Amouei et al. (105). Serointensity associations with suicide attempts, even when significant, such as Arling et al., Okusaga et al., and Zhang et al. are not presented and studies thus appear as carrying no significant association with T. gondii serology [Modified and reprinted with permission from (105); Copyright (2020); with permission from John Wiley & Sons; License # 4963420399853].
Figure 5Trait Impulsivity (SSS-V Disinhibition) by Age, Sex, and T. gondii IgG Status (N = 949). Among younger men aged 20–59 years old, T. gondii seropositivity was significantly associated with higher impulsive sensation-seeking (SSS-V Disinhibition) (p < 0.01). The two age groups are separated by median age (60 years). T. gondii IgG (–), T. gondii IgG seronegative, T. gondii IgG+, T. gondii IgG seropositive, SSV = Sensation Seeking Scale-V [Reprinted with permission from (114); Copyright (2015); with permission from Elsevier; License # 4964160181012].
Figure 6Trait Reactive Aggression (FAF) by Age, Sex, and T. gondii IgG Status (N = 949). Women, but not men, had a significant (p < 0.01) association between T. gondii IgG seropositivity and higher trait reactive aggression scores (determined by the FAF-Fragebogen zur Erfassung von Aggressivitätsfaktoren). T. gondii IgG (–), T. gondii IgG seronegative, T. gondii IgG+, T. gondii IgG seropositive. The two age groups are separated by median age (60 years). The overall reactive aggression scores are higher in men, but T. gondii-positive women have a similar level of reactive aggression with men. [Reprinted with permission from (114); Copyright (2015); with permission from Elsevier; License # 4964160181012].
Figure 7Composite Impulsivity and Aggression (age as covariate) in T. gondii seronegative (–) and seropositive (+) participants with history of Intermittent Explosive Disorder. Impulsivity (aggression) refers to Composite Impulsivity scores with Composite Aggression scores as a covariate; aggression (impulsivity) refers to Composite Aggression scores with Composite Impulsivity scores as a covariate. NS, not significant; *p ≤ 0.05. Significantly elevated Aggression and Impulsivity scores in T. gondii positives. Reciprocally adjusting impulsivity and aggression for each other yields a significant association with T. gondii only for Aggression [Reprinted with permission from (117); Copyright 2016, Physicians Postgraduate Press. Reprinted by permission].
Figure 8State and Trait Anxiety, Anger, and Depression (z) scores (age as covariate) in T. gondii seronegative (–) and seropositive (+) participants. z scores were used to place all symptom measures on the same scale. NS, not significant; p < 0.10; *p ≤ 0.05. While State and Trait Anxiety and Depression were not significantly different between T. gondii-positive and T. gondii-negative participants with Intermittent Explosive Disorder, the State and Trait Anger is significantly higher in T. gondii-positive participants relative to T. gondii-negative participants [Reprinted with permission from (117); Copyright 2016, Physicians Postgraduate Press. Reprinted by permission].
Figure 9Endophenotypes for suicidal behavior. Comparisons of impulsivity scores between T. gondii IgG-seronegative vs. T. gondii IgG-seropositive individuals and high vs. low phenylalanine/ tyrosine ratio (Phe:Tyr) stratified by gender and groups. Scoring significantly higher on impulsivity scores than other groups required four coexistent criteria, i.e., for a participant to be male, young, T. gondii-positive, and in the upper quartile of Phe:Tyr. Impulsivity scores in seronegative vs. seropositive participants stratified by Phe:Tyr categories, gender, and age. Disinhibition subscale of the Sensation Seeking Scale-V [SSS-V (DIS)] was used to obtain impulsivity scores, which are represented as standard errors (SEs) and least square means (adjusted for age in the age category and stratified by categorical variable). The following strata were included: older women (aged ≥ 60 years), older men (aged ≥ 60 years), younger women (aged 20–59 years), and younger men (aged 20–59 years). If the Phe:Tyr ratio was in the lower 75th percentile, it was considered LOW and if the ratio was in top 25th percentile, it was considered HIGH. Statistically significant interactions were uncovered between T. gondii seropositivity, gender, age category, and Phe:Tyr ratio upon performing ANCOVA analysis of impulsivity scores [F(1, 896) = 7.772, p = 0.007]. A significant interaction between Phe:Tyr ratio and T. gondii seropositivity status was present in younger men [F(1, 173) = 10.635, p = 0.001], but it was not significant in other strata {i.e., older women [F(1, 84) = 1.868, p = 0.173), younger women [F(1, 280) = 0.516, p = 0.473], older men [F(1, 256) = 0.593, p = 0.442]}. *Upon performing Tukey's Honestly Significant Difference Test, the impulsivity scores were significantly higher in younger men who had HIGH Phe:Tyr ratios and were also T. gondii-seropositive, as compared to all other subgroups (p < 0.01 for all). Additional significant differences within the subgroups were not present [Reprinted with permission from (115); Copyright (2018); with permission from Elsevier; License # 4964311353323].
Figure 10Graphic illustration of norepinephrine (NE) synthesis in the brain of a rodent. Synthesis of NE occurs from tyrosine through the following steps: (a) tyrosine hydroxylase converts tyrosine to levodopa or l-3,4-dihydroxyphenylalanine (L-DOPA); (b) L-type amino acid decarboxylase converts L-DOPA to dopamine; (c) vesicular monoamine transporter (VMAT) transports dopamine into the presynaptic vesicles; and (d) dopamine-β-hydroxylase (DBH) converts dopamine into NE. NE binding to β- and α- adrenergic receptors takes place after its release from the presynaptic vesicles into the synapse, from where norepinephrine transporter (NET) mediates its reuptake. Locus coeruleus (LC) houses the majority of brainstem noradrenergic neurons and it projects to several regions in the brain, including the amygdala, hippocampus and medial prefrontal cortex (MPC) [Reprinted from (363); Copyright (2020); with permission from Elsevier; License # 4986231317003].
Figure 11Schematic illustrating the regulation of inflammatory response by noradrenergic neurotransmission during an infection in the rodent brain. (A) Norepinephrine (NE, green triangles) is released from locus coeruleus noradrenergic neurons that are functioning normally. NE binds to adrenergic receptors located on immune cells, astrocytes, neurons, and microglia. Microglia and GABAergic neurons are activated by NE, cells that help with downregulation of pro-inflammatory cytokines and neuronal dendrite repair. (B) In rodents, neurons have been reported to undergo several changes in response to chronic T. gondii infection, including severe reduction in NE and dopamine-β-hydroxylase (DBH), within noradrenergic neurons, redistribution of GAD67 (an enzyme involved in GABA synthesis), and loss of dendritic spines. Additionally, reduced glutamate transporter Glt-1 has been observed in astrocytes of rodents chronically infected with T. gondii. Elevation in the levels of inflammatory cytokines, including interleukin (IL)-1β, tumor necrosis factor (TNF) and interferon (IFN)-γ also occurs. The model from Laing et al. states that since noradrenergic signaling is suppressed during chronic T. gondii infection, the brakes on inflammation are lifted leading to increased cytokine concentrations. The behavioral alterations seen in rodents chronically infected with T. gondii could be partly explained by these changes. (C) Laing et al. suggest that the elevated pro-inflammatory cytokines can be suppressed and the lack of NE can be compensated for (at least partially) by treating the T. gondii-infected rodents with Guanabenz (a noradrenergic agonist), which has been linked with reversal of T. gondii infection-induced hyperlocomotion in rodents) [Reprinted from (363); Copyright (2020); with permission from Elsevier; License # 4986231317003].